



Published in final edited form as:

ACS Nano. 2012 October 23; 6(10): 8970–8982. doi:10.1021/nn303030t.

Synthesis and *In Vivo* Pharmacokinetic Evaluation of Degradable Shell Crosslinked Polymer Nanoparticles with Poly(carboxybetaine) vs. Poly(ethylene glycol) Surface-grafted Coatings

Ang Li^{1,‡}, Hannah P. Luehmann^{2,‡}, Guorong Sun¹, Sandani Samarajeewa¹, Jiong Zou¹, Shiyi Zhang¹, Fuwu Zhang¹, Michael J. Welch^{2,§}, Yongjian Liu^{2,*}, and Karen L. Wooley^{1,*}

¹Department of Chemistry and Department of Chemical Engineering, Texas A&M University, College Station, Texas 77842, United States

²Department of Radiology, Washington University in St. Louis, Missouri 63110, United States

Abstract

Nanoparticles with tunable pharmacokinetics are desirable for various biomedical applications. Poly(ethylene glycol) (PEG) is well known to create “stealth” effects to stabilize and extend the blood circulation of nanoparticles. In this work, poly(carboxybetaine) (PCB), a new non-fouling polymer material, was incorporated as surface-grafted coatings, conjugated onto degradable shell crosslinked knedel-like nanoparticles (dSCKs) composed of poly(acrylic acid)-based shells and poly(lactic acid) (PLA) cores, to compare the *in vivo* pharmacokinetics to their PEG-functionalized analogs. A series of five dSCKs was prepared from amphiphilic block copolymers, having different numbers and lengths of either PEG or PCB grafts, by supramolecular assembly in water followed by shell crosslinking, and then studied by a lactate assay to confirm their core hydrolytic degradabilities. Each dSCK was also conjugated with 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) macrocyclic chelators and tyramine moieties to provide for ⁶⁴Cu and/or radiohalogen labeling. The high specific activity of ⁶⁴Cu radiolabeling ensured nanogram administration of dSCKs for *in vivo* evaluation of their pharmacokinetics. Biodistribution studies demonstrated comparable *in vivo* pharmacokinetic profiles of PCB-grafted dSCKs to their PEG-conjugated counterparts. These results indicated that PCB-functionalized dSCKs have great potential as a theranostic platform for translational research.

Keywords

Pharmacokinetic; biodistribution; radiolabeling; poly(carboxybetaine); poly(ethylene glycol); nanomedicine; shell crosslinked knedel-like nanoparticles

Over the past decade, nanoparticles have been increasingly employed as delivery vehicles for diagnostic and therapeutic applications, owing to the multifunctionality and multivalency.^{1–8} For different biomedical applications, it is of paramount importance to control the pharmacokinetics and biodistribution of nanoparticles, which can be achieved through tuning their physicochemical properties, such as shapes, sizes, internal compositions, external surface charges and functionalities.^{9–13} It's well known that

*Corresponding Author Address correspondence to wooley@mail.chem.tamu.edu; liuyo@mir.wustl.edu..

‡These authors contributed equally.

§This work is dedicated to Dr. Michael J. Welch, who passed away on May 6th, 2012.

nanoparticles are prone to be sequestered by the mononuclear phagocyte system (MPS), which is triggered by the adsorption of plasma proteins onto nanoparticles.¹⁴ Thus, “stealth” nanoparticles are needed to minimize the protein adsorption and avoid the MPS clearance. Currently, the most widely used strategy to empower nanoparticles with “stealthy” functions is grafting poly(ethylene glycol) (PEG), which is non-toxic, water-soluble and of low immunogenic response, onto the nanoparticle surface to prevent protein binding.^{15–17} Although the mechanism is still controversial, studies suggested that it is the water barrier, created by strong hydrogen bonding with water molecules from its ether groups that resists proteins from approaching the surface.

However, the PEG coating has been reported with disadvantages for *in vivo* applications, such as the lack of functional groups for post-modification, interference with cell uptake and endosome escape of nanoparticles,¹⁸ accelerated blood clearance after the second dose caused by the development of anti-PEG antibodies by the immune system,^{19,20} potential *in vivo* degradation through oxidation by superoxide anions and H₂O₂ generated by polymorphonuclear leukocytes (PMN) and macrophages,^{21–23} and the loss of biological activity of PEGylated therapeutic proteins.^{24–26} Therefore, there have been continuous efforts to develop new materials, which are non-toxic, less immune-toxic, functionalizable and simple to synthesize, to outperform PEG. Among the many investigated materials, poly(zwitterions)s, especially poly(carboxybetaine)s (PCB) have attracted tremendous attention, due to its superior resistance to non-specific protein adsorption.^{27–32} It was reported that PCB-grafted gold nanoparticles showed better *in vitro* stability than the PEGylated counterparts.³³ More importantly, the PCB coating could retain the bioactivity of the biomolecules, more effectively than could PEG, indicating the great potential of using PCB-modified nanoparticles for pre-clinical and translational research.^{34–36}

Among various types of nanoparticles, shell crosslinked knedel-like (SCK) nanoparticles (SCK) have drawn particular attention, owing to the high loading capacity in the hydrophobic core and controlled payloads release from the hydrophilic shell, together with the unique attributes of stability and controlled shell transport that arise from the crosslinking.^{37–42} Recently, we have developed a facile and efficient “pre-grafting” methodology to incorporate mPEG and (DOTA) chelator with quantitatively-controlled densities onto SCKs for tunable *in vivo* pharmacokinetics and radiolabeling specific activities,^{43,44} which therefore was employed in this study for PCB and PEG conjugation onto SCKs.

In the development of nanomaterials for personalized medicine, concerns have increased consistently on the *in vivo* fate, clearance, and toxicity of nanoparticles in nanomedicine health risk evaluation, which makes biodegradable polymeric nanoparticles the most attractive candidates for potential clinical applications. Poly(lactic acid) (PLA) is a commonly-used material for nanoparticle construction, largely because of its degradability *via* hydrolysis and biosafety of the degradation product, lactic acid.^{45–47}

Driven by our interest in developing multivalent nanoparticles with controlled *in vivo* pharmacokinetics, while retaining high bioactivity for theranostic applications, a diblock amphiphilic copolymer poly(acrylic acid)-*b*-poly(lactide) (PAA-*b*-PLA) was grafted with PCB or PEG chains and sites for radiolabeling, assembled into micelles and shell crosslinked to prepare PLA-core degradable SCKs (dSCK). This robust “pre-grafting” strategy involved combinations of reversible addition-fragmentation chain transfer (RAFT) polymerization, ring-opening polymerization (ROP), supramolecular assembly and chemical conjugation. The degradability of dSCKs was analyzed with lactate assay. The *in vivo* biodistribution profiles of PCB- or PEG-conjugated dSCKs were tracked by ⁶⁴Cu

radiolabeling through DOTA chelator conjugated within the PAA shell. Specifically, this work provides a new platform with tunable properties for nanoparticle translational research.

RESULTS AND DISCUSSION

The amphiphilic diblock copolymer PAA₇₅-*b*-PLA₃₃, which served as the precursor to all of the dSCK materials, was obtained by sequential RAFT polymerization of *tert*-butyl acrylate (*t*BA) and ROP of lactide (LA), followed by acidolysis upon the treatment of trifluoroacetic acid (TFA). The order of two polymerizations was chosen to enable fine tuning of the hydrophobic PLA chain length, while maintaining the length of PAA segment constant. This combined RAFT polymerization and ROP required a bifunctional RAFT chain transfer agent (CTA) **1**, having a trithiocarbonate for RAFT polymerization and a terminal hydroxyl group that can facilitate ROP. The CTA was synthesized *via* esterification of 2-(dodecylthiocarbonothioylthio)-2-methylpropionic acid and 1,5-pentanediol, as shown in Figure 1. Proton NMR spectroscopy of **1** showed a series of characteristic chemical shifts, including those of methylene protons adjacent to the ester group at 4.10 ppm, methylene protons next to the hydroxyl group at 3.63 ppm, and the methyl group from C12 chain of the CTA at 0.88 ppm, and the integration intensity ratios agreed with the theoretical values (see experimental section for details). The poly(*tert*-butyl acrylate) with a terminal hydroxyl group (P*t*BA₇₅-OH, **2**) was then afforded by RAFT polymerization of *t*BA by using **1** as the chain transfer agent, 2,2'-azobis(isobutyronitrile) (AIBN, 10 mol %) as the thermal radical initiator and 2-butanone (50 vol %) as the solvent at 56 °C, with the feed ratio of [*t*BA]:[**1**] = 100:1. The polymerization was quenched after 4.5 h when the monomer conversion was measured to be 75% by ¹H NMR spectroscopy. The well-defined structure of **2** was verified by gel permeation chromatography (GPC) analysis, with a monomodal molecular weight distribution (MWD), a polydispersity index (PDI) of 1.12, and a number-average molecular weight (M_n^{GPC}) of 11000 Da, which is close to the theoretical molecular weight ($M_n^{\text{theo.}} = 10050$ Da) calculated by ¹H NMR spectroscopy. The diblock copolymer, P*t*BA₇₅-*b*-PLA₃₃ (**3**) was afforded by chain extension of LA from macroinitiator **2** *via* 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU)-catalyzed ROP in dichloromethane ([**2**]:[LA]:[DBU] = 1:38:1.2). The organo-catalyzed ROP was chosen to construct the PLA second block is due to the high initiation and polymerization efficiency at room temperature, as well as the absence of any metal contamination that might cause problems for ⁶⁴Cu radiolabeling (*vide infra*).^{48,49} The polymerization was quenched after 1 h by adding several drops of acetic acid when monomer conversion was determined to be 85 % by ¹H NMR spectroscopy. The successful growth of the second block was verified by the observation of a complete shift of the GPC traces from the retention time of the first block **2**, to the diblock copolymer **3** at shorter retention time. The well-defined structure of the diblock copolymer was also confirmed by the good agreement between molecular weight determined by GPC to the theoretical value ($M_n^{\text{theo.}} = 14400$ Da, $M_n^{\text{GPC}} = 16200$ Da), and a monomodal MWD and narrow PDI of 1.08. ¹H NMR spectroscopy further demonstrated the construction of the PLA block by comparing the integration ratio between methylene protons (2.36-2.13 ppm) from P*t*BA and methine protons (5.23-5.10 ppm) from PLA. Complete removal of the *tert*-butyl groups of **3** was achieved by TFA treatment for 2 h at room temperature, affording the amphiphilic diblock copolymer PAA₇₅-*b*-PLA₃₃, **4**.

By simple amidation, polymer grafts as well as small molecule moieties with primary amine groups can be incorporated onto PAA. In order to prepare dSCKs with comparable molecular weight PEGs and PCBs as polymer grafts, monoamine-functionalized PCB samples having molecular weights (MW) of 2 kDa and 5 kDa, equivalent MW to commercially-available monoamine-functionalized, methoxy-terminated poly(ethylene glycol) (2 kDa and 5 kDa), were synthesized by RAFT polymerizations. A similar PCB polymer with a terminal amine group was reported by Jiang *et al.* by applying atom transfer

radical polymerization (ATRP) of 2-*tert*-butoxy-*N*-(2-(methacryloxy)ethyl)-*N,N*-dimethyl-2-oxoethanaminium bromide (CB-*t*Bu monomer) with 2-aminoethyl 2-bromoisobutyrate trifluoroacetate as the initiator, and 1,1,4,7,10,10-hexamethyltriethylenetetramine (HMTETA)/CuBr as the catalyst.³¹ However, in our study, any trace amount of copper salt impurities might cause inefficient radiolabeling of ⁶⁴Cu, thus, in order to overcome the potential issue of metal contamination, we chose RAFT polymerization to construct PCB grafts with terminal amine groups to be used as polymer grafts. Our initial model study showed that RAFT polymerization of *N*-(2-(acryloyloxy)ethyl)-2-(*tert*-butoxy)-*N,N*-dimethyl-2-oxoethanaminium bromide with **1** as the chain transfer agent, AIBN as the initiator, *N,N*-dimethylformamide (DMF) as the solvent at 70 °C could afford well-defined PCB polymers with controllable MWs, however conjugation of the hydroxyl group-terminated PCB grafts onto PAA-*b*-PLA copolymer was not successful, due to the relatively low reaction efficiency of esterification compared to amidation. To introduce terminal primary amine groups into PCBs, we designed and synthesized a functionalized RAFT chain transfer agent, 2-aminoethyl-2-(dodecylthiocarbonothioylthio)-2-methylpropanoate trifluoroacetate (**5**), by esterification between 2-(dodecylthiocarbonothioylthio)-2-methylpropionic acid and *N*-(*tert*-butoxycarbonyl) ethanolamine, followed by TFA treatment (Figure 2). The structure was confirmed by ¹H NMR, ¹³C NMR, and IR spectroscopies, and high-resolution mass spectrometry. The RAFT polymerizations were conducted under optimized conditions, [**5**]: [monomer] = 1:20, in DMF at 70 °C. The polymerizations were quenched after 0.7 h and 3 h, after monomer conversions had reached 40 % and 90 %, respectively. The well-defined structures of PCBs (**6**: 2 kDa PCB; **7**: 5 kDa PCB) were confirmed by GPC analyses showing monomodal MWDs and narrow PDIs of 1.16 for **6** and 1.08 for **7**, respectively (Figure 2). The well-controlled characteristic was also confirmed by the agreement of the degree of polymerization (DP) values that were calculated from monomer conversion and chain end analysis integration ratio of the methyl protons resonating at 0.88 ppm from the C12 chain of the CTA unit vs. the acrylate methylene protons α - to the ammonium group (-CH₂N(CH₃)₂CH₂CH₂OOC-) observed at 4.20-3.87 ppm by ¹H NMR spectroscopy.

To minimize the water exposure time, which may cause premature hydrolysis of the PLA segment, conjugations of 2-aminoethyl-mono-amide-DOTA-tris(*t*-Bu ester), tyramine, mPEG-NH₂ (2 kDa and 5 kDa) or PCB-NH₂ (**6** and **7**) were conducted in a one-step manner by standard amidation chemistry in DMF at room temperature, as shown in Figure 3. DOTA was selected as the chelator for ⁶⁴Cu because of its FDA approval and broad applications in clinical trials,⁵⁰ and tyramine is well-known to be labeled effectively by radioactive halogens.^{51,52} The amounts of functional moieties were controlled by adjusting the stoichiometry of each molecule relative to **4**. The actual incorporation of each unit was determined by ¹H NMR spectroscopy, by calculating from the integrals corresponding to characteristic protons from each unit. It should be noted, however, that the conjugates of **4** with PCB grafts exhibited poor solubility in DMF, DMSO and water, probably due to strong electrostatic interactions between PAA carboxylic acid groups and the PCB quaternary ammonium groups, thus no characterization was performed before the following deprotection step. The *tert*-butyl groups of the DOTA units and PCB grafts were subsequently removed by acidolysis, upon treatment with TFA. The polymers after deprotection were purified by dialysis against nanopure water followed by lyophilization, affording PEG-grafted block terpolymers **8**, **9**, and **10**, with five PEG of 2 kDa MW (5 PEG2k), five PEG grafts of PEG 5 kDa (5 PEG5k), and ten PEG grafts of 5 kDa (10 PEG5k), respectively, and PCB-grafted block terpolymers **11** and **12**, with five PCB grafts of 2 kDa and 5 kDa (5 PCB2k and 5 PCB5k), respectively.

The overall strategy for the preparation of the series of dSCKs, having variable lengths and densities of PEG or PCB surface grafts is illustrated in Figure 4. A rapid, direct dissolution

method was applied to prepare micelles from the grafted block terpolymer precursors, **8–12**, to avoid hydrolysis of PLA, as may occur during the conventional solvent displacement method that involves relatively long water exposure times. To facilitate radiolabeling, 1.0 mg/mL micelle solutions were prepared by directly dissolving each polymer precursor (**8–12**) into nanopure water, followed by extensive stirring for 2 h. Then, the dSCKs were obtained by crosslinking of the hydrophilic shell domain through amidation of approximately 20% of the carboxylic acid groups by reaction with crosslinker 2,2'-(ethylenedioxy) bis(ethylamine) (EDDA), followed by purification by dialysis overnight. The dSCKs were characterized by transmission electron microscopy (TEM), dynamic light scattering (DLS) and zeta potential (ζ -potential) measurements. As shown in Table 1, each **dSCK1-5** displayed < 100 nm size, as measured in the dry state by TEM and in aqueous solution by DLS (number average) (Figure 5). Moreover, with increased PEG chain length from 2 kDa (**dSCK1**) to 5 kDa (**dSCK2**) the ζ -potential increased from -41 ± 4 mV to -28 ± 3 mV, and with further increased density of 5 kDa PEG to 10 per polymer chain (**dSCK3**), the ζ -potential remained similar (-25 ± 4 mV). This trend indicated that increasing the length and density of the PEG grafts, more effectively shielded the negative charge character of the PAA shell, driving the ζ -potential of the dSCK nanoparticles closer to neutral. In contrast to the shielding effects from PEG, zwitterionic PCB grafts provided the dSCKs (**dSCK4** and **dSCK5**) with strong negatively-charged characteristic, which is in agreement with reported results.³¹

Nanoparticle stability in serum is an important criterion for their *in vivo* biomedical applications. By monitoring the hydrodynamic diameter changes for the dSCKs over time in the presence of 10% bovine serum albumin (BSA), we investigated the stabilities of **dSCK1-5** with PEG or PCB grafts in 10 % BSA solution at 37 °C. As shown in Figure 6, all of the dSCKs were stable over 12 h with only slight changes of their sizes, except for **dSCK5**, which exhibited *ca.* 15 % size increase. The subtle instability behavior of the nanoparticle presenting the longer PCB chains is under further investigation to determine the potential causes and biological effects *in vitro* and *in vivo*. Overall, the results are consistent with a previous study that found that both the presence of PEG and PCB could inhibit protein adsorption onto nanoparticles, which can potentially extend the blood circulation time.

To evaluate the degradability of dSCKs, we studied the degradation of the dSCKs at 37 °C in pH 7.4 and pH 5.0 PBS, which represent physiological pH and endosomal/lysosomal or tumor tissue pH, respectively. The degradation was measured by the production of lactic acid, which is the final degradation molecule resulting from the hydrolysis of PLA, using a commercially-available lactate assay tool kit. As shown in Figure 7, after 15 days both PEG-grafted and PCB-grafted dSCKs showed certain extents of LA production, with PCB-grafted dSCKs having faster degradation than the PEG-grafted dSCKs. More specifically, at pH 7.4, **dSCK1** and **dSCK4** having 5 PEG2k and 5 PCB2k per polymer chain, underwent 10% and 19% LA release; with 5 PEG5k grafted **dSCK2** and 5 PCB5k grafted **dSCK5**, 14% and 22% LA release was observed, respectively. We propose that the differences in degradation rates originated from the nature of PEG and PCB. PEG obtains its water solubility from the ability of binding water molecules by hydrogen bonding of its ether groups, while zwitterionic PCB, bearing both positive and negative charges, gains the non-fouling property by strong ionic structuring of water molecules, which may transfer water-soluble molecules, such as lactic acid and oligo-PLA faster than PEG, resulting in faster degradation of the PLA core or the release of the degradation product out of the dSCKs. In addition, dSCKs with longer polymer grafts (**dSCK2** vs. **dSCK1**; **dSCK5** vs. **dSCK4**) or higher density of polymer grafts on the shell (**dSCK3** vs. **dSCK2**) showed more LA release over 15 days. With similar trend of degradation profiles at pH 7.4, the LA release in PBS 5.0 buffer was slower, which was probably due to a combination of factors, such as slower release of oligo-

PLA from the core through the crosslinked PAA-based shell barrier and slower hydrolysis of PLA inside/outside the core region. Slower rates of PLA hydrolysis within the pH range of *ca.* 5 have been reported for hydrophobic PLA bulk samples and surface grafts.^{53–56} The differences in degradation rates for these core-shell dSCK nanoparticles having PCB *vs.* PEG surface grafts and under physiological *vs.* acidic pH may be utilized to control the release of imaging or therapeutic payloads.

We next studied the ⁶⁴Cu radiolabeling efficiency of dSCKs. All the dSCKs could be labeled with high specific activity through the DOTA chelator on the PAA shell (Table 1). Serum stability studies showed that after size exclusion column purification, **dSCK1-5** had high (>95%) radiochemical purity. During the 24 h incubation with mouse serum, there was almost no decrease of radiochemical purity for each individual dSCK. All the radiochemical purities of the ⁶⁴Cu-dSCKs were still more than 93%, as shown in Figure 8.

The effect of PEG chain length grafted to dSCKs on their *in vivo* pharmacokinetics is clearly depicted in Figure 9. With the increasing MW of PEG from 2 kDa to 5 kDa, the blood retention of **dSCK2** was significantly ($p < 0.05$, $n = 4$) enhanced at each individual time point in contrast to **dSCK1** (3 fold at 1 h, 6 fold at 4 h and 24 h). The hepatic and splenic accumulations were both greatly reduced, while the kidney clearance was increased at the same time. Interestingly, the bone and gastrointestinal (GI) tract (stomach and intestine) uptakes of **dSCK2** were also elevated during the study, reasonably due to the increased blood retention. However, the further increase of number of 5 kDa PEG from 5 to 10 per dSCK polymer precursor chain did not enhance the blood retention proportionally. As shown in Figure 8, the biodistribution of **dSCK3** was very similar to that of **dSCK2**, with a slightly better renal clearance.

Although **dSCK1** (2 kDa PEG) and **dSCK4** (2 kDa PCB) had different surface coatings, they had similar physicochemical properties, including size and surface charge. The pharmacokinetic evaluation displayed similar initial blood retention with about 10% ID/g at 1 h post injection in C57BL/6 mice (Figure 10). However, the 2 kDa PEG grafted **dSCK1** had a faster clearance, leading to a quick drop of blood retention to less than half of that obtained with 2 kDa PCB conjugated **dSCK4** at 4 h p.i. Also, the MPS accumulations (liver and spleen) of **dSCK1** were all significantly ($p < 0.05$, $n = 4$) higher than those acquired with **dSCK4**, although both particles maintained constant MPS uptakes during the 24 h study. Interestingly, in contrast to the main hepatic and splenic clearance of **dSCK1**, the major excretion pathway for **dSCK4** was through kidney (>16% ID/g at 24 h). Further, both particles had similar distributions in other organs, including bone and gastrointestinal (GI) tract (Figure 10).

In contrast to **dSCK4**, the 5 kDa PCB grafted **dSCK5** showed greatly improved blood retention at 1 h although its size was about twice big as **dSCK4**. However, it rapidly dropped to a level similar to **dSCK4** at later time points (4 h and 24 h). The liver accumulations were slightly higher, while the spleen uptakes were very similar. Also, the kidney clearance was significantly ($p < 0.05$, $n = 4$) decreased during the 24 h period, reasonably owing to the size effect.

Compared to **dSCK5**, **dSCK2** had extended blood pool retention including blood, lung and heart, comparable liver and spleen accumulations, but enhanced kidney clearance. Again, this could be due to the effect of **dSCK5**'s size. Interestingly, consistent with the comparison between **dSCK1** and **dSCK4**, the bone uptake for **dSCK2** increased over time and was significantly ($p < 0.05$, $n = 4$) higher than that acquired with **dSCK4** at 4 h and 24 h p.i.

CONCLUSIONS

In summary, a series of **dSCK1-5** nanoparticles was prepared through a “pre-grafting” strategy with controlled sizes and surface charges, by designing, synthesizing and coupling an amphiphilic diblock copolymer of acrylic acid and lactide, and complementary monoamino-terminated zwitterionic PCB polymer grafts of varying lengths or comparable commercially-available monoamino-PEG grafts. All dSCKs were radiolabeled with ^{64}Cu in high specific activities and showed extended serum stabilities. The *in vivo* pharmacokinetic evaluation indicated that the 2 kDa PCB-grafted **dSCK4** had a slightly better biodistribution profile than did the 2 kDa PEG-grafted analog **dSCK1**, while longer chain (5 kDa) PEG grafts imparted **dSCK2** with superior biodistribution to that of the corresponding 5 kDa PCB-grafted nanoparticles, **dSCK5**. All the dSCKs demonstrated pH-dependent degradation kinetics *in vitro*, with the PCB-grafted nanoparticles undergoing faster hydrolysis. These results suggest that PCB, as a new type of functionalizable anti-protein adsorption material, demonstrates comparable effects in tuning degradable polymer nanoparticle biodistributions. Further studies will be performed to compare their immunotoxicities and also the targeting efficiency of PCB-grafted dSCKs vs. PEG-functionalized dSCKs with positron emission tomography. The outcome from these studies may lay the foundation for using PCB as a versatile platform to design degradable nanoparticles for *in vivo* theranostics.

EXPERIMENTAL SECTION

Instrumentation

^1H NMR and ^{13}C NMR spectra were recorded on Varian Inova 300 MHz or Varian Mercury 300 MHz spectrometers interfaced to a UNIX computer using VnmrJ software. Chemical shifts were referred to the solvent resonance signals. IR spectra were recorded on an IR Prestige 21 system (Shimadzu Corp., Japan) and analyzed using IRsolution v. 1.40 software.

Tetrahydrofuran (THF) Gel permeation chromatography (GPC) was performed on a Waters Chromatography, Inc., 1515 isocratic HPLC pump equipped with an inline degasser, a model 2414 differential refractometer (Waters, Inc.), and four PLgel polystyrene-*co*-divinylbenzene gel columns (Polymer Laboratories, Inc.) connected in series: 5 μm Guard (50 \times 7.5 mm), 5 μm Mixed C (300 \times 7.5 mm), 5 μm 10⁴ (300 \times 7.5 mm), and 5 μm 500 Å (300 \times 7.5 mm) using the Breeze (version 3.30, Waters, Inc.) software. The instrument was operated at 35 °C with THF as eluent (flow rate set to 1.0 mL/min). Polymer solutions were prepared at a concentration of *ca.* 3 mg/mL and an injection volume of 200 μL was used. The system was calibrated with polystyrene standards (Polymer Laboratories, Amherst, MA). The DMF gel permeation chromatography (GPC) was conducted on a Waters Chromatography, Inc. (Milford, MA) system equipped with an isocratic pump model 1515, a differential refractometer model 2414, and a four-column set of 5 μm Guard (50 \times 7.5 mm), Styragel HR 4 5 μm DMF (300 \times 7.5 mm), Styragel HR 4E 5 μm DMF (300 \times 7.5 mm), and Styragel HR 2 5 μm DMF (300 \times 7.5 mm). The system was equilibrated at 70 °C in prefiltered DMF containing 0.05 M LiBr, which served as polymer solvent and eluent (flow rate set to 1.00 mL/min). Polymer solutions were prepared at a concentration of *ca.* 3 mg/mL and an injection volume of 200 μL was used. Data collection and analysis were performed with Empower 2 v. 6.10.01.00 software (Waters, Inc.). The system was calibrated with poly(ethylene glycol) standards (Polymer Laboratories, Amherst, MA).

Glass transition temperatures (T_g) were measured by differential scanning calorimetry on a Mettler-Toledo DSC822^e (Mettler-Toledo, Inc., Columbus, OH), with a heating rate of 10 °C/min. Measurements were analyzed using Mettler-Toledo Star^e v. 10.00 software. The T_g was taken as the midpoint of the inflection tangent, upon the third heating scan. Thermogravimetric analysis was performed under N₂ atmosphere using a Mettler-Toledo

model TGA/DSC 1, with a heating rate of 5 °C/min. Measurements were analyzed using Mettler-Toledo Star^c v. 10.00 software.

TEM samples were prepared by depositing *ca.* 5 μL of sample to carbon coated copper grids. Excess sample was wicked off using filter paper and the grids were allowed to dry in air for 10 min. The grids were then stained with 5 μL of 1% phosphotungstic acid (PTA) and excess stain was wicked off using filter paper. Specimens were observed on a JEOL 1200EX transmission electron microscope operating at 100 kV and micrographs were recorded at calibrated magnifications using an SIA-15C CCD camera. The number-average particle diameters (D_{av}) and standard deviations were generated from the analysis of particles from at least two different micrographs.

Dynamic light scattering (DLS) measurements were conducted using Delsa Nano C from Beckman Coulter, Inc. (Fullerton, CA) equipped with a laser diode operating at 658 nm. Size measurements were made in water ($n = 1.3329$, $\eta = 0.890$ cP at 25 ± 1 °C; $n = 1.3293$, $\eta = 0.547$ cP at 50 ± 1 °C; $n = 1.3255$, $\eta = 0.404$ cP at 70 ± 1 °C). Scattered light was detected at 165° angle and analyzed using a log correlator over 70 accumulations. The photomultiplier aperture and the attenuator were automatically adjusted to obtain a photon counting rate of *ca.* 10 kcps. The calculations of the particle size distribution and distribution averages were performed using CONTIN particle size distribution analysis routines. The samples in the glass sizing cell were equilibrated at the desired temperature for 5 min before measurements were made. The peak average of histograms from intensity, volume, or number distributions out of 70 accumulations was reported as the average diameter of the particles. The particle zeta potentials were determined by a Delsa Nano C particle analyzer (Beckman Coulter, Fullerton, CA) equipped with a 30 mW dual laser diode (658 nm). The zeta potential of the particles in suspension was obtained by measuring the electrophoretic movement of charged particles under an applied electric field. Scattered light was detected at a 30° angle at 25 °C. The zeta potential was measured at five regions in the flow cell and a weighted mean was calculated. These five measurements were used to correct for electroosmotic flow that was induced in the cell due to the surface charge of the cell wall. All determinations were repeated 5 times.

Materials

All Chemicals and reagents were purchased from Aldrich Chemical Co. and used as received, unless otherwise noted. *Tert*-butyl acrylate was passed through a neutral alumina column to remove the inhibitor before use. 2,2'-Azobis(isobutyronitrile) (AIBN) was recrystallized twice from methanol before use. Lactide was recrystallized twice from hexanes/ethyl acetate before use. Dichloromethane (CH_2Cl_2) was distilled over CaH_2 and stored under N_2 before use. The lactate colorimetric assay kit (ab65331) was purchased from Abcam®. 2-Aminoethyl-mono-amide-DOTA-tris(*t*-Bu ester) was purchased from Macrocyclics, Inc. Monoamine-functionalized, methoxy-terminated poly(ethylene glycol)s were purchased from Rapp Polymere The. Spectra/Por dialysis membrane tubes were purchased from Spectrum Medical Industries Inc. Nanopure water (18 $\text{M}\Omega\text{-cm}$) was acquired by means of a Milli-Q water filtration system, Millipore Corp. (Bedford, MA).

5-hydroxypentyl 2-(dodecylthiocarbonothioylthio)-2-methylpropanoate (1)

To a 250 mL RB flask equipped with a stir bar was placed 2-(dodecylthiocarbonothioylthio)-2-methylpropionic acid (3.08 g, 8.45 mmol), 1,5-pentanediol (4.28 g, 41.1 mmol) and 4-(dimethylamino)pyridine (0.205 g, 1.67 mmol). Dry THF (50 mL) was then added into the flask to dissolve all reagents followed by dropwise addition of a solution of *N,N*'-dicyclohexylcarbodiimide (2.05 g, 9.85 mmol) in THF. The reaction mixture was allowed to stir at room temperature for 12 h. The solid was removed by

filtration, and the filtrate was concentrated under vacuum and purified by silica gel flash chromatography eluting with ethyl acetate/hexanes (1:2). The product was afforded as a yellow oil. Yield: 62%. IR (cm^{-1}): 3547–3180, 2921, 2848, 1728, 1458, 1381, 1258, 1157, 1126, 1064, 810. ^1H NMR (300 MHz, CDCl_3 , δ , ppm) 4.10 (t, 2H, $J = 6.3$ Hz, $\text{CH}_2\text{OC}(\text{O})$), 3.63 (t, 2H, $J = 6.5$ Hz, CH_2OH), 3.26 (t, 2H, $J = 7.3$ Hz, $\text{CH}_2\text{SC}(\text{S})$), 1.72–1.58 (m, 12H, $\text{HOCH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{OC}(\text{O})$, $(\text{CH}_3)_2\text{C}$, $\text{CH}_2\text{CH}_2\text{S}$), 1.47–1.29 (m, 20H, $\text{HO}(\text{CH}_2)_2\text{CH}_2(\text{CH}_2)_2\text{OC}(\text{O})$, $\text{S}(\text{CH}_2)_2(\text{CH}_2)_9\text{CH}_3$), 0.88 (t, 3H, $J = 6.6$ Hz, CH_3CH_2). ^{13}C NMR (75 MHz, CDCl_3 , δ , ppm) 221.6, 173.1, 66.1, 62.8, 56.1, 37.0, 32.4, 32.0, 29.8, 29.7, 29.6, 29.5, 29.2, 29.1, 28.3, 28.0, 25.5, 22.8, 22.4, 14.3. HRMS (m/z): calcd for $\text{C}_{22}\text{H}_{42}\text{O}_3\text{S}_3$, 450.2296; found, 451.2374 [$\text{M} + \text{H}$] $^+$.

Synthesis of P*t*BA₇₅-OH (2)

To a 25 mL Schlenk flask with a stir bar and sealed by a rubber septum was charged with *t*BA (8.52 g, 66.6 mmol), 5-hydroxypentyl 2-(dodecylthiocarbonothioylthio)-2-methylpropanoate (300 mg, 0.666 mmol), AIBN (10.9 mg, 0.0664 mmol, 10 mol %), and 10 mL of 2-butanone as the solvent. After three cycles of freeze-pump-thaw, the flask was placed in an oil bath at 56 °C. The polymerization was quenched after 4.5 h when the monomer conversion was measured to be 75% by ^1H NMR. The polymer solution was precipitated three times in methanol/ H_2O (2:1). The product was collected and dried under vacuum for 24 h at room temperature to afford **2** as a yellow solid. Yield: 4.85 g (72%, based on 75% conversion of *t*BA). $M_n^{\text{theo.}} = 10050$ Da, $M_n^{\text{GPC}} = 11000$ Da, $M_w/M_n = 1.12$. IR (cm^{-1}): 3070–2792, 1728, 1450, 1365, 1249, 1141, 840, 748. ^1H NMR (300 MHz, CDCl_3 , ppm) δ 4.04 (t, $-\text{CH}_2\text{OC}(\text{O})$), 3.65 (t, $-\text{CH}_2\text{OH}$), 3.32 (t, $-\text{CH}_2\text{SC}(\text{S})-$), 2.36–2.13 (br, $>\text{CHC}(\text{O})-$ of polymer backbone), 1.92–1.09 (br, alkyl chain of CTA, $>\text{C}(\text{CH}_3)_2$ of CTA, $\text{HOCH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{O}-$, $-\text{CH}_2-$ of polymer back bone, *tert*-butyl group of *t*BA units), 0.87 (t, $-\text{CH}_3$ of CTA chain end). ^{13}C NMR (75 MHz, CDCl_3 , ppm) δ 174.4–173.9, 80.6–80.2, 42.6–41.8, 37.5–34.9, 28.3. $T_g = 41$ °C. TGA in N_2 : 195–215 °C, 40% mass loss; 215–440 °C, 40% mass loss.

Synthesis of P*t*BA₇₅-*b*-PLA₃₃(3)

To a 250 mL Schlenk flask with a stir bar and sealed by a rubber septum was charged with P*t*BA₇₅-OH (**2**) (2.04 g, 0.203 mmol), D,L-lactide (1.15 g, 7.79 mmol), and 80 mL of dry dichloromethane as the solvent. The polymerization was initiated by adding DBU (36.4 mg, 0.239 mmol) stock solution *via* N_2 -washed syringe. The polymerization was quenched after 1 h by adding several drops of acetic acid when the monomer conversion was measured to be 85% by ^1H NMR. The polymer solution was precipitated three times in methanol/ H_2O (2:1). The product was collected and dried under vacuum for 24 h at room temperature to afford **3** as a yellow solid. Yield: 2.40 g (80%, based on 85% conversion of D,L-LA). $M_n^{\text{theo.}} = 14400$ Da, $M_n^{\text{GPC}} = 16200$ Da, $M_w/M_n = 1.08$. IR (cm^{-1}): 3055–2824, 1743, 1728, 1450, 1366, 1250, 1142, 1088, 849, 748. ^1H NMR (300 MHz, CDCl_3 , ppm) δ 5.23–5.10 (m, $>\text{CHCH}_3$ of PLA), 4.20–4.01 (m, $-\text{CH}_2\text{OC}(\text{O})$), 3.32 (t, $-\text{CH}_2\text{SC}(\text{S})-$), 2.36–2.13 (br, $>\text{CHC}(\text{O})-$ of P*t*BA polymer backbone), 1.92–1.09 (br, alkyl chain of CTA, $>\text{C}(\text{CH}_3)_2$ of CTA, $\text{HOCH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{O}-$, $-\text{CH}_2-$ of polymer back bone, *tert*-butyl group of *t*BA units, $-\text{CH}_3$ of PLA), 0.87 (t, $-\text{CH}_3$ of CTA chain end). ^{13}C NMR (75 MHz, CDCl_3 , ppm) δ 174.4–173.9, 169.8–169.4, 80.6–80.4, 69.3–67.0, 42.6–41.8, 37.6–36.0, 28.2, 16.9–16.8. $T_g(\text{P*t*BA}) = 40$ °C, $T_g(\text{PLA}) = 51$ °C. TGA in N_2 : 200–240 °C, 25% mass loss; 240–360 °C, 40% mass loss.

Synthesis of PAA₇₅-*b*-PLA₃₃ (4)

To a 250 mL flamed-dried RB flask with a stir bar was charged with P*t*BA₇₅-*b*-PLA₃₀ (**3**) (2.00 g, 0.0694 mmol). Trifluoroacetic acid (TFA, 150 mL) was added to dissolve the

polymer and the reaction was allowed to stir 2 h at room temperature, after which the TFA was removed under vacuum. The crude product was dissolved in 100 mL DMF and transferred to a pre-soaked dialysis tubing (MWCO 6–8 kDa), and dialysis against nanopure water for two days. The aqueous was lyophilized to yield yellow solid of **4**. Yield: 1.10 g, 78%. $M_n^{\text{theo.}} = 10200$ Da. IR (cm^{-1}): 3579–2731, 1720, 1643, 1442, 1381, 1180, 1249, 1087, 918, 864, 802. ^1H NMR (300 MHz, DMSO- d_6 , ppm) δ 12.42–12.10 (br, $-\text{COOH}$), 5.23–5.10 (m, $>\text{CHCH}_3$ of PLA), 4.20–4.07 (m, $-\text{CH}_2\text{OC}(\text{O})-$), 3.32 (t, $-\text{CH}_2\text{SC}(\text{S})-$), 2.28–2.03 (br, $>\text{CHC}(\text{O})-$ of P*t*BA polymer backbone), 1.84–1.09 (br, alkyl chain of CTA, $>\text{C}(\text{CH}_3)_2$ of CTA, $\text{HOCH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{O}-$, $-\text{CH}_2-$ of polymer back bone, $-\text{CH}_3$ of PLA), 0.81 (t, $-\text{CH}_3$ of CTA chain end). ^{13}C NMR (75 MHz, CDCl_3 , ppm) δ 175.9–175.6, 169.3–169.0, 69.1–68.1, 16.5. $T_g(\text{PLA}) = 50$ °C, $T_g(\text{PAA}) = 120$ °C. TGA in N_2 : 195–215 °C, 40% mass loss; 215–370 °C, 30% mass loss.

2-(*tert*-butoxycarbonylamino)ethyl 2-(dodecylthiocarbonothioylthio)-2-methylpropanoate

To a 100 mL RB flask equipped with a stir bar was placed 2-(dodecylthiocarbonothioylthio)-2-methylpropionic acid (2.14 g, 5.87 mmol), *N*-(*tert*-butoxycarbonyl)ethanolamine (0.946 g, 5.87 mmol) and 4-(dimethylamino)pyridine (0.143 g, 1.17 mmol). Dry CH_2Cl_2 (30 mL) was then added into the flask to dissolve all reagents followed by dropwise addition of a solution of *N,N*-dicyclohexylcarbodiimide (1.45 g, 7.03 mmol) in CH_2Cl_2 . The reaction mixture was allowed to stir at room temperature for 12 h. The solid was removed by filtration, and the filtrate was concentrated under vacuum and purified by silica gel flash chromatography eluting with ethyl acetate/hexanes (1:8). The product was afforded as a yellow oil. Yield: 78%. IR (cm^{-1}): 3471–3279, 2924, 2854, 1712, 1504, 1458, 1365, 1250, 1157, 1064, 818. ^1H NMR (300 MHz, CDCl_3 , δ , ppm) 4.73 (br, 1H, $\text{NHC}(\text{O})$), 4.16 (t, 2H, $J = 4.8$ Hz, $\text{CH}_2\text{OC}(\text{O})$), 3.36 (t, 2H, $J = 4.8$ Hz, CH_2NH), 3.26 (t, 2H, $J = 7.5$ Hz, $\text{CH}_2\text{SC}(\text{S})$), 1.69 (s, 9H, $(\text{CH}_3)_3\text{C}$), 1.45–1.40 (m, 12H, $\text{HOCH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{OC}(\text{O})$, $(\text{CH}_3)_2\text{C}$, $\text{CH}_2\text{CH}_2\text{S}$), 1.32–1.17 (m, 18H, $\text{S}(\text{CH}_2)_2(\text{CH}_2)_9\text{CH}_3$), 0.88 (t, 3H, $J = 6.6$ Hz, CH_3CH_2). ^{13}C NMR (75 MHz, CDCl_3 , δ , ppm) 222.3, 173.1, 155.9, 79.6, 65.5, 56.1, 39.7, 37.2, 32.1, 29.8, 29.6, 29.5, 29.3, 29.1, 28.6, 28.0, 25.6, 22.9, 14.3. HRMS (m/z): calcd for $\text{C}_{24}\text{H}_{45}\text{NO}_4\text{S}_3$, 507.2511; found, 530.2448 [$\text{M} + \text{Na}$] $^+$.

2-aminoethyl 2-(dodecylthiocarbonothioylthio)-2-methylpropanoate trifluoroacetate (5)

At 0 °C, trifluoroacetic acid (8.10 mL, 105 mmol) was added to a solution of 2-(*tert*-butoxycarbonylamino)ethyl 2-(dodecylthiocarbonothioylthio)-2-methylpropanoate (525 mg, 1.034 mmol) in dry CH_2Cl_2 (5 mL) and the reaction mixture was stirred at this temperature for 30 min and at room temperature for another 30 min. The solvent and TFA were removed under vacuum and purified by silica gel flash chromatography eluting with MeOH/ CH_2Cl_2 (1:5). The product was afforded as a yellow oil. Yield: 69%. IR (cm^{-1}): 2924, 2854, 2345, 1728, 1674, 1458, 1257, 1188, 1141, 1064, 817. ^1H NMR (300 MHz, CDCl_3 , δ , ppm) 8.08 (br, 3H, $\text{TFA}^- \cdot \text{NH}_3^+\text{CH}_2$), 4.37 (t, 2H, $J = 5.1$ Hz, $\text{CH}_2\text{OC}(\text{O})$), 3.35–3.17 (m, 4H, $\text{CH}_2\text{SC}(\text{S})$, $\text{TFA}^- \cdot \text{NH}_3^+\text{CH}_2\text{CH}_2$), 1.72–1.61 (m, 8H, $(\text{CH}_3)_2\text{C}$, $\text{CH}_2\text{CH}_2\text{S}$), 1.38–1.21 (m, 18H, $\text{S}(\text{CH}_2)_2(\text{CH}_2)_9\text{CH}_3$), 0.88 (t, 3H, $J = 6.6$ Hz, CH_3CH_2). ^{13}C NMR (75 MHz, CDCl_3 , δ , ppm) 222.7, 173.7, 165.2, 105.2, 62.4, 56.1, 39.4, 37.5, 32.1, 29.8, 29.7, 29.6, 29.5, 29.3, 29.2, 27.9, 25.2, 22.9, 14.3. HRMS (m/z): calcd for $\text{C}_{21}\text{H}_{38}\text{F}_3\text{NO}_4\text{S}_3$, 521.1915; found, 520.9540 [$\text{M} - \text{H}$] $^-$.

N-(2-(acryloyloxy)ethyl)-2-(*tert*-butoxy)-*N,N*-dimethyl-2-oxoethanaminium bromide

2-(dimethylamino)ethyl acrylate (10.0 g, 69.8 mmol), *tert*-butyl bromoacetate (19.7 g, 101 mmol) were reacted in 40 mL acetonitrile for 24 h at 50 °C under N_2 . The product was yielded as white solid by slowly adding 500 mL ethyl ether to the reaction mixture. The

solvent was removed under vacuum for 24 h at room temperature. Yield: 83%. IR (cm^{-1}): 3610–3255, 3008, 2924, 1720, 1635, 1458, 1396, 1242, 1188, 1141, 979, 918, 810. ^1H NMR (300 MHz, D_2O , δ , ppm) 6.48 (dd, 1H, $J = 17$ and 1.0 Hz, *cis* $\text{CHH}=\text{CHCO}$ -), 6.22 (dd, 1H, $J = 17$ and 9.0 Hz, $\text{CH}_2=\text{CHCO}$ -), 6.06 (dd, 1H, $J = 9.0$ and 1.0 Hz, $\text{CHH}=\text{CHCO}$ -), 4.67 (t, 2H, $J = 4.2$ Hz, $-\text{CH}_2\text{N}(\text{CH}_3)_2\text{CH}_2\text{CH}_2\text{OOC}$ -), 4.33 (s, 2H, $-\text{CH}_2\text{N}(\text{CH}_3)_2\text{CH}_2\text{CH}_2\text{OOC}$ -), 4.04 (t, 2H, $J = 4.2$ Hz, $-\text{CH}_2\text{N}(\text{CH}_3)_2\text{CH}_2\text{CH}_2\text{OOC}$ -), 3.37 (s, 6H, $-\text{CH}_2\text{N}(\text{CH}_3)_2\text{CH}_2\text{CH}_2\text{OOC}$ -), 1.52 (s, 9H, $(\text{CH}_3)_3\text{C}$ -). ^{13}C NMR (75 MHz, DMSO-d_6 , δ , ppm) 164.7, 163.9, 132.4, 127.7, 84.0, 62.1, 61.4, 57.9, 51.7, 27.6. HRMS (m/z): calcd for $\text{C}_{13}\text{H}_{24}\text{BrNO}_4$, 337.0889; found, 336.0790 $[\text{M} - \text{H}]^-$.

Synthesis of 2 kDa PCB (6)

To a 25 mL Schlenk flask with a stir bar and sealed by a rubber septum was charged with 2-aminoethyl 2-(dodecylthiocarbonothioylthio)-2-methylpropanoate trifluoroacetate (CTA) (110 mg, 0.192 mmol), *N*-(2-(acryloyloxy)ethyl)-2-(*tert*-butoxy)-*N,N*-dimethyl-2-oxoethanaminium bromide (1.43 g, 4.23 mmol), AIBN (6.91 mg, 0.0421 mmol, 20 mol %), and 10 mL of DMF as the solvent. After three cycles of freeze-pump-thaw, the flask was placed in an oil bath at 70 °C. The polymerization was quenched after 40 min when the monomer conversion was measured to be 40 % by ^1H NMR. The polymer solution was precipitated three times in ethyl acetate. The product was collected and dried under vacuum for 24 h at room temperature to afford PCB-2K as a yellow solid. Yield: 0.35 g (61%, based on 40% conversion of monomer). $M_n^{\text{theo.}} = 3200$ Da, $M_w/M_n = 1.16$. IR (cm^{-1}): 3672–3217, 2924, 1728, 1627, 1458, 1373, 1250, 1149, 987, 841. ^1H NMR (300 MHz, DMSO-d_6 , ppm) δ 8.10 (br, $\text{TFA}^- \cdot \text{NH}_3^+ \text{CH}_2$), 4.83–4.37 (br, $\text{TFA}^- \cdot \text{NH}_3^+ \text{CH}_2\text{CH}_2\text{OC}(\text{O})$ -, $-\text{CH}_2\text{N}(\text{CH}_3)_2\text{CH}_2\text{CH}_2\text{OOC}$ -), 4.20–3.87 (br, $-\text{CH}_2\text{N}(\text{CH}_3)_2\text{CH}_2\text{CH}_2\text{OOC}$ -), 3.56–3.24 (br, $-\text{CH}_2\text{N}(\text{CH}_3)_2\text{CH}_2\text{CH}_2\text{OOC}$ -, $\text{CH}_2\text{SC}(\text{S})$, $\text{TFA}^- \cdot \text{NH}_3^+ \text{CH}_2\text{CH}_2$), 2.47–2.30 (br, $>\text{CHC}(\text{O})$ - of polymer backbone), 1.93–1.16 (m, alkyl chain of CTA, $>\text{C}(\text{CH}_3)_2$ of CTA, $-\text{CH}_2$ - of polymer back bone, *tert*-butyl groups), 0.85 (t, $-\text{CH}_3$ of CTA chain end). ^{13}C NMR (75 MHz, MeOD, δ , ppm) 166.5, 165.4–164.9, 86.5, 64.8–64.0, 53.3, 37.1, 31.8–31.0, 28.5. $T_g = 116$ °C

Synthesis of 5 kDa PCB (7)

To a 25 mL Schlenk flask with a stir bar and sealed by a rubber septum was charged with 2-aminoethyl 2-(dodecylthiocarbonothioylthio)-2-methylpropanoate trifluoroacetate (CTA) (100 mg, 0.192 mmol), *N*-(2-(acryloyloxy)ethyl)-2-(*tert*-butoxy)-*N,N*-dimethyl-2-oxoethanaminium bromide (1.29 g, 3.81 mmol), AIBN (6.28 mg, 0.0383 mmol, 20 mol %), and 9 mL of DMF as the solvent. After three cycles of freeze-pump-thaw, the flask was placed in an oil bath at 70 °C. The polymerization was quenched after 3.0 h when the monomer conversion was measured to be 90 % by ^1H NMR. The polymer solution was precipitated three times in ethyl acetate. The product was collected and dried under vacuum for 24 h at room temperature to afford PCB-5K as a yellow solid. Yield: 0.47 g (40%, based on 90% conversion of monomer). $M_n^{\text{theo.}} = 6600$ Da, $M_w/M_n = 1.08$. $T_g = 130$ °C.

Synthesis of PEG/PCB, DOTA, tyramine grafted PAA-*b*-PLA (8–12)

Grafting PEG/PCB, 2-aminoethyl-mono-amide-DOTA-tris(*t*-Bu ester), tyramine onto PAA₇₅-*b*-PLA₃₃ (**4**) involved the following: to a anhydrous *N,N*-dimethylformamide (DMF) solution of **4**, 1-[3'-(dimethylamino)propyl]-3-ethylcarbodiimide methiodide (EDCI), and 1-hydroxybenzotriazole (HOBt) were added. The mixtures were allowed to stir for 1 h at room temperature, followed by the addition of mono amine PEGs or PCBs. After 30 min, DMF solution of the mixture of 2-aminoethyl-mono-amide-DOTA-tris(*t*-Bu ester), tyramine and *N,N*-diisopropylethylamine (DIPEA) was added, followed by further stirring for 30 h. The relative feed ratios of DOTA and tyramine to **4** were kept constant at 5:5:1, whereas the

PEG/PCB to **4** feed ratios were 7:1 when targeting five grafts per polymer chain, and 20:1 when targeting ten grafts per polymer chain, respectively. The grafted polymers were purified by dialyzing against nanopure H₂O (18.2 MΩ-cm) for 3 d to remove organic solvent and byproducts. The aqueous solutions were then lyophilized to afford the products as white solid with yield of 60–80%. PCB grafted polymer were not characterized due to the poor solubility. ¹H NMR (300 MHz, DMSO-d₆, ppm) δ 7.05–6.87 (br, aromatic protons from tyramine), 6.73–6.59 (br, aromatic protons from tyramine), 5.24–5.11 (m, >CHCH₃ of PLA), 3.56–3.19 (br, -OCH₂CH₂O- from PEG backbone, -CH₂CO- from DOTA, -CH₂CH₂NH- from tyramine), 2.40–2.05 (br, >CHC(O)- of polymer backbone, >NCH₂CH₂N< from DOTA), 1.67–0.98 (br, alkyl chain of CTA, >C(CH₃)₂ of CTA, -CH₂- of polymer back bone, *tert*-butyl groups from DOTA, -CH₃ of PLA).

Graft polymer precursor for **8** with five 2 kDa PEG

PAA₇₅-*b*-PLA₃₃ (30 mg, 2.9 μmol), EDCI (17 mg, 57 μmol), HOBt (7.9 mg, 58 μmol), tyramine (2.0 mg, 14 μmol), 2-aminoethyl-mono-amide-DOTA-tris(*t*-Bu ester) (10 mg, 14 μmol), mPEG₂₀₀₀-NH₂ (41 mg, 20 μmol), DIPEA (19 mg, 0.15 mmol). Yield: 70%.

Graft polymer precursor for **9** with five 5 kDa PEG

PAA₇₅-*b*-PLA₃₃ (30 mg, 2.9 μmol), EDCI (17 mg, 57 μmol), HOBt (7.9 mg, 58 μmol), tyramine (2.0 mg, 14 μmol), 2-aminoethyl-mono-amide-DOTA-tris(*t*-Bu ester) (10 mg, 14 μmol), mPEG₅₀₀₀-NH₂ (103 mg, 20.6 μmol), DIPEA (19 mg, 0.15 mmol). Yield: 80%.

Graft polymer precursor for **10** with ten 5 kDa PEG

PAA₇₅-*b*-PLA₃₃ (30 mg, 2.9 μmol), EDCI (17 mg, 57 μmol), HOBt (7.9 mg, 58 μmol), tyramine (2.0 mg, 14 μmol), 2-aminoethyl-mono-amide-DOTA-tris(*t*-Bu ester) (10 mg, 14 μmol), mPEG₅₀₀₀-NH₂ (294 mg, 58.8 μmol), DIPEA (19 mg, 0.15 mmol). Yield: 73%.

Graft polymer precursor for **11** with five 2 kDa PCB

PAA₇₅-*b*-PLA₃₃ (30 mg, 2.9 μmol), EDCI (17 mg, 57 μmol), HOBt (7.9 mg, 58 μmol), tyramine (2.0 mg, 14 μmol), 2-aminoethyl-mono-amide-DOTA-tris(*t*-Bu ester) (10 mg, 14 μmol), **6** (64 mg, 20.6 μmol), DIPEA (45 mg, 0.35 mmol).

Graft polymer precursor for **12** with five 5 kDa PCB

PAA₇₅-*b*-PLA₃₃ (30 mg, 2.9 μmol), EDCI (17 mg, 57 μmol), HOBt (7.9 mg, 58 μmol), tyramine (2.0 mg, 14 μmol), 2-aminoethyl-mono-amide-DOTA-tris(*t*-Bu ester) (10 mg, 14 μmol), **7** (136 mg, 20.6 μmol), DIPEA (45 mg, 0.35 mmol).

Deprotection to afford polymer **8–12**

Polymers and TFA (200 equiv. to *tert*-butyl groups) were allowed to stir for 2 h, followed by removal of TFA under vacuum, dialysis against nanopure H₂O and lyophilization to afford final polymer precursors as white solid with yield of 70–80%. ¹H NMR of PEG-grafted polymers (300 MHz, DMSO-d₆, ppm) δ 7.05–6.87 (br, aromatic protons from tyramine), 6.73–6.59 (br, aromatic protons from tyramine), 5.41–5.26 (m, >CHCH₃ of PLA), 4.81–3.92 (br, -OCH₂CH₂O- from PEG backbone, -CH₂CO- from DOTA, -CH₂CH₂NH- from tyramine), 2.40–2.05 (br, >CHC(O)- of polymer backbone, >NCH₂CH₂N< from DOTA), 1.67–0.98 (br, alkyl chain of CTA, >C(CH₃)₂ of CTA, -CH₂- of polymer back bone). ¹H NMR of PCB-grafted polymers (300 MHz, TFA-d, ppm) δ 7.13–6.07 (br, aromatic protons from tyramine), 6.90–6.80 (br, aromatic protons from tyramine), 5.24–5.11 (m, >CHCH₃ of PLA), 3.56–3.19 (br, -CH₂N(CH₃)₂CH₂CH₂OOC-, -CH₂N(CH₃)₂CH₂CH₂OOC-, -CH₂CO- from DOTA, -CH₂CH₂NH- from tyramine), 2.73–2.36 (br, >CHC(O)- of polymer

backbone, $>NCH_2CH_2N<$ from DOTA), 1.95–1.25 (m, alkyl chain of CTA, $>C(CH_3)_2$ of CTA, $-CH_2-$ of polymer back bone, $-CH_3$ of PLA), 0.86–0.79 (br, $-CH_3$ of CTA chain end).

Preparation of dSCK1-5

The micelles were prepared by direct dissolving polymer precursors into nanopure H₂O with polymer concentration *ca.* 1 mg/mL. The SCKs were prepared by adding 2,2-(ethylenedioxy)-bis(ethylamine) (EDDA) in nanopure H₂O dropwise. The reaction was allowed to stir for 2 h at room temperature. EDCI in nanopure H₂O was then added to the solution dropwise. The stoichiometry applied to achieve 20% nominal crosslinking was 10:1:2.2 for carboxylic acid unites/EDCI/EDDA. The crosslinking reactions were further stir at room temperature for 12. The final SCKs were obtained after dialyzing against nanopure water overnight.

dSCK2 with five 5 kDa PEG

$(D_h)_n$ (DLS) = 30 ± 9 nm, $(D_h)_v$ (DLS) = 45 ± 27 nm, $(D_h)_i$ (DLS) = 162 ± 125 nm; ζ -potential: -28 ± 1.5 mV.

dSCK1 with five 2 kDa PEG

$(D_h)_n$ (DLS) = 40 ± 12 nm, $(D_h)_v$ (DLS) = 61 ± 39 nm, $(D_h)_i$ (DLS) = 279 ± 238 nm; ζ -potential: -41 ± 1.3 mV.

dSCK3 with ten 5 kDa PEG

$(D_h)_n$ (DLS) = 32 ± 9 nm, $(D_h)_v$ (DLS) = 47 ± 28 nm, $(D_h)_i$ (DLS) = 175 ± 141 nm; ζ -potential: -25 ± 2.2 mV.

dSCK4 with five 2 kDa PCB

$(D_h)_n$ (DLS) = 65 ± 19 nm, $(D_h)_v$ (DLS) = 94 ± 49 nm, $(D_h)_i$ (DLS) = 223 ± 143 nm; ζ -potential: -58 ± 4.8 mV.

dSCK5 with five 5 kDa PEG

$(D_h)_n$ (DLS) = 29 ± 8 nm, $(D_h)_v$ (DLS) = 43 ± 27 nm, $(D_h)_i$ (DLS) = 195 ± 173 nm; ζ -potential: -50 ± 2.6 mV.

dSCK *in vitro* size stability study

dSCKs were incubated with 10 wt% BSA solution at 37 °C under gentle stirring. At each time point, an aliquot of SCK solution was collected to measure the size using dynamic light scattering (DLS).

dSCK *in vitro* degradation study

dSCK solutions in PBS 7.4 buffer and PBS 5.0 buffer were prepared by dissolving lyophilized dSCK powder by the buffer solution with concentrations of *ca.* 1 mg/mL. The solutions were incubated at 37 °C. At each time point, the lactic acid levels were measured by lactate assay kit (abcam®, ab65331), the degradation percentages were calculated using calibration curve with DL-lactic acid as the standard. The experiments were performed in duplicates.

⁶⁴Cu radiolabeling dSCKs

⁶⁴Cu (half-life = 12.7 h, β^+ = 17%, β^- = 40%) was produced on the Washington University Medical School CS-15 cyclotron by the ⁶⁴Ni (p,n) ⁶⁴Cu nuclear reaction at a specific

activity of 50–200 mCi/mg at the end of bombardment.⁵⁹ Degradable **dSCK1-5** (~4.5 μg) were incubated with 18.5 MBq of ^{64}Cu in 100 μL of 0.1 M pH 5.5 ammonium acetate buffer at 45°C for 1 h (n = 3). After ethylene diamine tetraacetic acid (EDTA) challenge (10 mM in 50 mM, pH 7.4, phosphate buffer), the radiochemical purities of the radiolabeled nanoparticles were measured by radioactive thin-layer chromatography (Bioscan, Washington DC), followed by the purification with 7k Zeba spin desalting column (Piercenet, Rockford, IL).

Serum stability study

The radiochemical purities of ^{64}Cu radiolabeled dSCKs were measured before the addition of mouse serum with 1:1 volume ratio. The ^{64}Cu -dSCKs and serum mixture was incubated in microcentrifuge tubes at 45°C. At each time point (1 h, 4 h, and 24 h post injection, p.i.), 10 μL of the sample was removed and incubated at 45°C with 5 μL of EDTA (10 mM in 50 mM pH 7.4 phosphate buffer) for 5 min. The radiochemical purities of the samples (n=3 for each dSCK) were tested using radioactive thin-layer chromatography (Bioscan, Washington DC).

In vivo biodistribution study

All animal studies were performed in compliance with guidelines set forth by the NIH Office of Laboratory Animal Welfare and approved by the Washington University Animal Studies Committee. *In vivo* biodistribution studies were performed using 185 kBq of ^{64}Cu -dSCKs (32–63 ng/mouse) in 100 μL saline (APP pharmaceuticals, Schaumburg, IL) injected *via* the tail vein of C57BL/6 mice weighing 20–25 g (n=4/group) under inhaled isoflurane. The mice were euthanized by cervical dislocation at each time point (1 h, 4 h, and 24 h p.i.). Organs of interest were collected, weighed, and counted in a well gamma counter (Beckman 8000). Standards were prepared and measured along with the organs to calculate the average and standard deviation of the percentage of the injected dose per gram of tissue (%ID/g).⁵⁸

Acknowledgments

This material is based upon work supported by the National Heart Lung and Blood Institute of the National Institutes of Health as a Program of Excellence in Nanotechnology (HHSN268201000046C). The Welch Foundation is gratefully acknowledged for support through the W. T. Doherty-Welch Chair in Chemistry, Grant No. A-0001. The authors thank Dr. M. Elsabahy for insightful discussions.

REFERENCES

1. Nyström AM, Wooley KL. The Importance of Chemistry in Creating Well-Defined Nanoscopic Embedded Therapeutics: Devices Capable of the Dual Functions of Imaging and Therapy. *Acc. Chem. Res.* 2011; 44:969–978. [PubMed: 21675721]
2. Brigger I, Dubernet C, Couvreur P. Nanoparticles in Cancer Therapy and Diagnosis. *Adv. Drug Deliv. Rev.* 2002; 54:631–651. [PubMed: 12204596]
3. Torchilin VP. Multifunctional Nanocarriers. *Adv. Drug Deliv. Rev.* 2006; 58:1532–1555. [PubMed: 17092599]
4. Wang AZ, Langer R, Farokhzad OC. Nanoparticle Delivery of Cancer Drugs. *Annu. Rev. Med.* 2012; 63:185–198. [PubMed: 21888516]
5. Liu Y, Welch MJ. Nanoparticles Labeled with Positron Emitting Nuclides: Advantages, Methods, and Applications. *Bioconjug. Chem.* 2012; 23:671–682. [PubMed: 22242601]
6. Elsabahy M, Wooley KL. Design of Polymeric Nanoparticles for Biomedical Delivery Applications. *Chem. Soc. Rev.* 2012; 41:2545–2561. [PubMed: 22334259]
7. Schober O, Rahbar K, Riemann B. Multimodality Molecular Imaging - from Target Description to Clinical Studies. *Eur. J. Nucl. Med. Mol. Imaging.* 2009; 36:302–314. [PubMed: 19130054]

8. Gref R, Minamitake Y, Peracchia MT, Trubetskoy V, Torchilin V, Langer R. Biodegradable Long-Circulating Polymeric Nanospheres. *Science*. 1994; 263:1600–1603. [PubMed: 8128245]
9. Khlebtsov N, Dykman L. Biodistribution and Toxicity of Engineered Gold Nanoparticles: A Review of *In Vitro* and *In Vivo* Studies. *Chem. Soc. Rev.* 2011; 40:1647–1671. [PubMed: 21082078]
10. Owens DE, Peppas NA. Opsonization, Biodistribution, and Pharmacokinetics of Polymeric Nanoparticles. *Int. J. Pharm.* 2006; 307:93–102. [PubMed: 16303268]
11. Li SD, Huang L. Pharmacokinetics and Biodistribution of Nanoparticles. *Mol. Pharmaceutics*. 2008; 5:496–504.
12. Venkataraman S, Hedrick JL, Ong ZY, Yang C, Ee PLR, Hammond PT, Yang YY. The Effects of Polymeric Nanostructure Shape on Drug Delivery. *Adv. Drug Deliv. Rev.* 2011; 63:1228–1246. [PubMed: 21777633]
13. Elsabahy M, Wooley KL. Strategies Toward Well-Defined Polymer Nanoparticles Inspired by Nature: Chemistry *versus* Versatility. *J. Polym. Sci., Part A: Polym. Chem.* 2012; 50:1869–1880.
14. Hume DA. The Mononuclear Phagocyte System. *Curr. Opin. Immunol.* 2006; 18:49–53. [PubMed: 16338128]
15. Vonarbourg A, Passirani C, Saulnier P, Benoit JP. Parameters Influencing the Stealthiness of Colloidal Drug Delivery Systems. *Biomaterials*. 2006; 27:4356–4373. [PubMed: 16650890]
16. Moghimi SM, Hunter AC, Murray JC. Long-Circulating and Target-Specific Nanoparticles: Theory to Practice. *Pharmacol. Rev.* 2001; 53:283–318. [PubMed: 11356986]
17. Peracchia MT, Vauthier C, Desmaële D, Gulik A, Dedieu JC, Demoy M, d'Angelo J, Couvreur P. Pegylated Nanoparticles from a Novel Methoxypolyethylene Glycol Cyanoacrylate-Hexadecyl Cyanoacrylate Amphiphilic Copolymer. *Pharm. Res.* 1998; 15:550–556. [PubMed: 9587950]
18. Mintezar MA, Simanek EE. Nonviral Vectors for Gene Delivery. *Chem. Rev.* 2009; 109:259–302. [PubMed: 19053809]
19. Ganson NJ, Kelly SJ, Scarlett E, Sundry JS, Hershfield MS. Control of Hyperuricemia in Subjects with Refractory Gout, and Induction of Antibody Against Poly(ethylene glycol) (PEG), in a Phase I Trial of Subcutaneous PEGylated Urate Oxidase. *Arthritis Res. Ther.* 2006; 8:R12. [PubMed: 16356199]
20. Armstrong JK, Hempel G, Koling S, Chan LS, Fisher T, Meiselman HJ, Garratty G. Antibody Against Poly(ethylene glycol) Adversely Affects PEG-Asparaginase Therapy in Acute Lymphoblastic Leukemia Patients. *Cancer*. 2007; 110:103–111. [PubMed: 17516438]
21. Ostuni E, Chapman RG, Holmlin RE, Takayama S, Whitesides GM. A Survey of Structure-Property Relationships of Surfaces that Resist the Adsorption of Protein. *Langmuir*. 2001; 17:5605–5620.
22. Shen M, Martinson L, Wagner MS, Castner DG, Ratner BD, Horbett TA. PEO-Like Plasma Polymerized Tetraglyme Surface Interactions with Leukocytes and Proteins: *In Vitro* and *In Vivo* Studies. *J. Biomater. Sci., Polym. Ed.* 2002; 13:367–390. [PubMed: 12160299]
23. Li L, Shen S, Jiang S. Protein Interactions with Oligo(ethylene glycol) (OEG) Self-Assembled Monolayers: OEG Stability, Surface Packing Density and Protein Adsorption. *J. Biomater. Sci., Polym. Ed.* 2007; 18:1415–1427. [PubMed: 17961324]
24. Gaberc-Porekar V, Zore I, Podobnik B, Menart V. Obstacles and Pitfalls in the PEGylation of Therapeutic Proteins. *Curr. Opin. Drug Discov. Devel.* 2008; 11:242–250.
25. Veronese FM, Mero A. The Impact of PEGylation on Biological Therapies. *Biodrugs*. 2008; 22:315–329. [PubMed: 18778113]
26. Chapman AP. PEGylated Antibodies and Antibody Fragments for Improved Therapy: A Review. *Adv. Drug Deliv. Rev.* 2002; 54:531–545. [PubMed: 12052713]
27. Vaisocherova H, Yang W, Zhang Z, Cao ZQ, Cheng G, Piliarik M, Homola J, Jiang SY. Ultralow Fouling and Functionalizable Surface Chemistry Based on a Zwitterionic Polymer Enabling Sensitive and Specific Protein Detection in Undiluted Blood Plasma. *Anal. Chem.* 2008; 80:7894–7901. [PubMed: 18808152]
28. Zhang Z, Chen SF, Jiang SY. Dual-Functional Biomimetic Materials: Nonfouling Poly(carboxybetaine) with Active Functional Groups for Protein Immobilization. *Biomacromolecules*. 2006; 7:3311–3315. [PubMed: 17154457]

29. Jiang S, Cao Z. Ultralow-Fouling, Functionalizable, and Hydrolyzable Zwitterionic Materials and Their Derivatives for Biological Applications. *Adv. Mater.* 2010; 22:920–932. [PubMed: 20217815]
30. Carr LR, Zhou Y, Krause JE, Xue H, Jiang S. Uniform Zwitterionic Polymer Hydrogels with a Nonfouling and Functionalizable Crosslinker Using Photopolymerization. *Biomaterials.* 2011; 32:6893–6899. [PubMed: 21704366]
31. Cao Z, Yu Q, Xue H, Cheng G, Jiang S. Nanoparticles for Drug Delivery Prepared from Amphiphilic PLGA Zwitterionic Block Copolymers with Sharp Contrast in Polarity Between Two Blocks. *Angew. Chem. Int. Ed.* 2010; 49:3771–3776.
32. Abraham S, So A, Unsworth LD. Poly(carboxybetaine methacrylamide)-Modified Nanoparticles: a Model System for Studying the Effect of Chain Chemistry on Film Properties, Adsorbed Protein Conformation, and Clot Formation Kinetics. *Biomacromolecules.* 2011; 12:3567–3580. [PubMed: 21892823]
33. Yang W, Zhang L, Wang S, White AD, Jiang S. Functionalizable and Ultra Stable Nanoparticles Coated with Zwitterionic Poly(carboxybetaine) in Undiluted Blood Serum. *Biomaterials.* 2009; 30:5617–5621. [PubMed: 19595457]
34. Keefe AJ, Jiang SY. Poly(zwitterionic) Protein Conjugates Offer Increased Stability without Sacrificing Binding Affinity or Bioactivity. *Nature Chem.* 2012; 4:60–64.
35. Veronese FM, Pasut G. PEGylation, Successful Approach to Drug Delivery. *Drug Discov. Today.* 2005; 10:1451–1458. [PubMed: 16243265]
36. Bailon P, Palleroni A, Schaffer CA, Spence CL, Fung WJ, Porter JE, Ehrlich GK, Pan W, Xu ZX, Modi MW, et al. Rational Design of a Potent, Long-Lasting Form of Interferon: A 40 kDa Branched Polyethylene Glycol-Conjugated Interferon α -2a for the Treatment of Hepatitis C. *Bioconjugate Chem.* 2001; 12:195–202.
37. Zhang L, Gu FX, Chan JM, Wang AZ, Langer RS, Farokhzad OC. Nanoparticles in Medicine: Therapeutic Applications and Developments. *Clin. Pharmacol. Ther.* 2008; 83:761–769. [PubMed: 17957183]
38. Torchilin VP. Nanoparticles in Cancer Therapy and Diagnosis. *Adv. Drug Deliv. Rev.* 2002; 54:235–252. [PubMed: 11897148]
39. Thurmond KB, Kowalewski T, Wooley KL. Shell Cross-linked Knedels: A Synthetic Study of the Factors Affecting the Dimensions and Properties of Amphiphilic Core-Shell Nanospheres. *J. Am. Chem. Soc.* 1997; 119:6656–6665.
40. Samarajeewa S, Shrestha R, Li YL, Wooley KL. Degradability of Poly(Lactic Acid)-Containing Nanoparticles: Enzymatic Access through a Cross-Linked Shell Barrier. *J. Am. Chem. Soc.* 2012; 134:1235–1242. [PubMed: 22257265]
41. Zhang SY, Li Z, Samarajeewa S, Sun GR, Yang C, Wooley KL. Orthogonally Dual-Clickable Janus Nanoparticles *via* a Cyclic Templating Strategy. *J. Am. Chem. Soc.* 2011; 133:11046–11049. [PubMed: 21732605]
42. Lin LY, Lee NS, Zhu JH, Nyström AM, Pochan DJ, Dorshow RB, Wooley KL. Tuning Core vs. Shell Dimensions to Adjust the Performance of Nanoscopic Containers for the Loading and Release of Doxorubicin. *J. Controlled Release.* 2011; 152:37–48.
43. Sun G, Hagooley A, Xu J, Nyström AM, Li Z, Rossin R, Moore DA, Wooley KL, Welch MJ. Facile, Efficient Approach to Accomplish Tunable Chemistries and Variable Biodistributions for Shell Cross-Linked Nanoparticles. *Biomacromolecules.* 2008; 9:1997–2006. [PubMed: 18510359]
44. Sun G, Xu J, Hagooley A, Rossin R, Li Z, Moore DA, Hawker CJ, Welch MJ, Wooley KL. Strategies for Optimized Radiolabeling of Nanoparticles for *In Vivo* PET Imaging. *Adv. Mater.* 2007; 19:3157–3162.
45. Tian HY, Tang ZH, Zhuang XL, Chen XS, Jing XB. Biodegradable Synthetic Polymers: Preparation, Functionalization and Biomedical Application. *Prog. Polym. Sci.* 2012; 37:237–280.
46. Anderson JM, Shive MS. Biodegradation and Biocompatibility of PLA and PLGA Microspheres. *Adv. Drug Deliv. Rev.* 1997; 28:5–24. [PubMed: 10837562]
47. Middleton JC, Tipton AJ. Synthetic Biodegradable Polymers as Orthopedic Devices. *Biomaterials.* 2000; 21:2335–2346. [PubMed: 11055281]

48. Lohmeijer BGG, Pratt RC, Leibfarth F, Logan JW, Long DA, Dove AP, Nederberg F, Choi J, Wade C, Waymouth RM, et al. Guanidine and Amidine Organocatalysts for Ring-Opening Polymerization of Cyclic Esters. *Macromolecules*. 2006; 39:8583.
49. Kiesewetter MK, E. J. Shin EJ, Hedrick JM, Waymouth RM. Organocatalysis: Opportunities and Challenges for Polymer Synthesis. *Macromolecules*. 2010; 43:2093–2107.
50. <http://clinicaltrials.gov/ct2/results?term=dota>
51. Almutairi A, Rossin R, Shokeen M, Hagooley A, Ananth A, Capoccia B, Guillaudeu S, Abendschein D, Anderson CJ, Welch MJ, et al. Biodegradable Dendritic Positron-Emitting Nanoprobes for the Noninvasive Imaging of Angiogenesis. *Proc. Natl. Acad. Sci. U.S.A.* 2009; 106:685–690. [PubMed: 19129498]
52. Adam MJ, Wilbur DS. Radiohalogens for Imaging and Therapy. *Chem. Soc. Rev.* 2005; 34:153–163. [PubMed: 15672179]
53. Makino K, Arakawa M, Kondo T. Preparation and *In Vitro* Degradation Properties of Polylactide Microcapsules. *Chem. Pharm. Bull.* 1985; 33:1195–1201. [PubMed: 4028300]
54. Belbella A, Vauthier C, Fessi H, Devissaguet JP, Puisieux F. *In vitro* Degradation of Nanospheres from Poly(D,L-lactides) of Different Molecular Weights and Polydispersities. *Int. J. Pharm.* 1996; 129:95–102.
55. Jung JH, Ree M, Kim H. Acid- and Base-Catalyzed Hydrolyses of Aliphatic Polycarbonates and Polyesters. *Catal. Today*. 2006; 115:283–287.
56. Xu LB, Crawford K, Gorman CB. Effects of Temperature and pH on the Degradation of Poly(lactic acid) Brushes. *Macromolecules*. 2011; 44:4777–4782.
57. McCarthy DW, Shefer RE, Klinkowstein RE, Bass LA, Margeneau WH, Cutler CS, Anderson CJ, Welch MJ. Efficient Production of High Specific Activity ^{64}Cu Using a Biomedical Cyclotron. *Nucl. Med. Biol.* 1997; 24:35–43. [PubMed: 9080473]
58. Liu YJ, Ibricevic A, Cohen JA, Cohen JL, Gunsten SP, Fréchet JMJ, Walter MJ, Welch MJ, Brody SL. Impact of Hydrogel Nanoparticle Size and Functionalization on *In Vivo* Behavior for Lung Imaging and Therapeutics. *Mol. Pharmaceutics*. 2009; 6:1891–1902.




Figure 1. Synthetic scheme for the preparation of amphiphilic diblock copolymer PAA₇₅-*b*-PLA₃₃, **4**, and GPC traces of intermediates P*t*BA₇₅-OH, **2**, and P*t*BA₇₅-*b*-PLA₃₃, **3**.




Figure 2. Synthetic scheme and GPC traces of poly(carboxybetaine) (PCB) grafts, **6** and **7**.




Figure 3.
Synthetic scheme of grafted polymers 8–12.




Figure 4.

A schematic illustration for the overall strategy for the preparation of degradable SCK (dSCK) by self assembly of multifunctional block graft polymers **8–12** into micelles, followed by crosslinking to afford **dSCK1-5**, having different lengths and numbers of PEG vs. PCB grafts per block copolymer chain to afford different PEG vs. PCB surface coverage of the dSCKs.




Figure 5. Left column: TEM images of (a) **dSCK1**; (b) **dSCK2**; (c) **dSCK3**; (d) **dSCK4**; (e) **dSCK5**. Right column: DLS histograms of (f) **dSCK1**; (g) **dSCK2**; (h) **dSCK3**, (i) **dSCK4**; (j) **dSCK5**. Scale bar = 100 nm.




Figure 6. **dSCK1-5** *in vitro* size stability measured by DLS in triplicate in 10 % bovine serum albumin (BSA) solution at 37 °C. (●) dSCK1; (◆) dSCK2; (▲) dSCK3; (▼) dSCK4; (■) dSCK5.




Figure 7. *In vitro* degradation of dSCKs in PBS pH = 7.4 buffer (solid lines) and PBS pH = 5.0 buffer (dashed lines) measured by lactate assay. (◆) dSCK1; (▲) dSCK2; (▼) dSCK3; (●) dSCK4; (■) dSCK5.




Figure 8. The radiochemical stability of ⁶⁴Cu-dSCKs in mouse serum at 45 °C.




Figure 9.
Biodistributions of (A) **dSCK1**, (B) **dSCK2**, and (C) **dSCK3**.




Figure 10.
Biodistributions of (A) **dSCK4** and (B) **dSCK5**.

Table 1

Physicochemical properties, ^{64}Cu radiolabeling specific activity of **dSCK1-5**.

	dSCK1	dSCK2	dSCK3	dSCK4	dSCK5
Polymer precursor	8	9	10	11	12
Polymer grafts	5 × PEG2k	5 × PEG5k	10 × PEG5k	5 × PCB2k	5 × PCB5k
D_h (nm) ^a	40 ± 2	30 ± 9	32 ± 9	29 ± 8	65 ± 19
Diameter (nm) ^b	18 ± 3	15 ± 4	14 ± 4	16 ± 4	32 ± 6
Zeta potential (mV)	-41 ± 4	-28 ± 3	-25 ± 4	-50 ± 5	-58 ± 4
^{64}Cu Specific Activity ($\mu\text{Ci}/\mu\text{g}$)	105.5	154.9	79.2	81.8	139.0

^a measured by DLS, number average

^b measured by TEM.